Key Drivers
- Strong profitability
- Robust liquidity
- Premium multiples
AIAI Summary
West has re‑rated from a defensive consumables story to a growth‑at‑a‑premium HVP/GLP‑1 play whose upside hinges on executing capacity/mix expansion and Annex‑1 conversions, while the premium valuation makes the stock highly sensitive to manufacturing bottlenecks, contract timing and leadership transition risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong profitability
- •Robust liquidity
- •Premium multiples
WST is a highly profitable, well‑capitalized cash generator with strong returns but limited upside due to high valuation and meaningful capex that constrains near‑term free cash conversion.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Near-term support
- •Mid-$240s resistance
Over last month WST showed a mildly downward short-term trend, slipping ~1.7% from $241.12 to $237.03 after a $254.34 peak while repeatedly testing mid-$240s resistance and probing support at $231.09, implying downside risk if $231 breaks.
Last month displayed ~10% high–low range with a peak at $254.34 and a test down to $231.09
Sentiment & News
Key News Insights:
- •Analyst upside
- •Institutional flux
- •Operational risks
West Pharmaceuticals draws strong analyst optimism and active institutional interest due to GLP‑1 demand and high-value components despite operational risks and an impending CEO transition.
Positive momentum and investor engagement likely support the stock near term, but execution risks and leadership turnover could increase volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings